92 results on '"Maraveyas A"'
Search Results
2. Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy
3. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool
4. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
5. Peri‐procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH
6. Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement
7. Cancer‐Associated ThrOmboSIs – Patient‐Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes
8. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study
9. Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study
10. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
11. Discordant reporting of VTE in pancreatic cancer: A systematic review and meta‐analysis of thromboprophylaxis versus chemotherapeutic trials
12. Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management
13. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
14. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis
15. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta‐analysis
16. Latest advances in preventing thromboembolic disease in the ambulatory oncology patient
17. Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)
18. The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism
19. Signal Transduction Peptide of Tissue Factor Phosphorylated at Ser258 and the Unphosphorylated STP in Urine Are Potential Biomarkers for Bladder Cancer
20. Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex
21. Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro
22. Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles
23. 125 VTE Risk Awareness in People with Lung Cancer in the UK: Results from a Patient-led National Survey
24. Tissue factor‐bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer
25. Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release
26. Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy
27. Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients
28. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
29. Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity
30. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
31. p38α phosphorylates serine 258 within the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived microparticles
32. Tumour and microparticle tissue factor expression and cancer thrombosis
33. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
34. Neoadjuvant Chemoradiotherapy for Resectable Oesophageal and Gastro-oesophageal Junction Cancer—Do We Need Another Randomised Trial?
35. Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB
36. The Effectiveness of Nurse Led 2-D Ultrasound Guided Insertion of Peripherally Inserted Central Catheters in Adult Patients: A Systematic Review
37. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
38. 13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer — Report of a Pilot Phase II Study
39. Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer.
40. CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study
41. Standardization of risk prediction model reporting in cancer‐associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancy
42. Primary Pulmonary NUT Carcinoma: Case Illustration and Updated Review of Literature
43. P-88 Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
44. PO-37: A study of the evolution of radiological features of untreated small volume pulmonary embolism (PE) in cancer patients
45. Reduction of streptavidin RYDS-mediated renal adhesion by site-directed mutagenesis
46. LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
47. LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)
48. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply
49. PO-66 Patient-reported outcome (PRO) assessment of symptom severity and impairment of daily activities in a group of ambulant cancer patients with IPE: correlation with the Hull score
50. PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.